Silo pharma's sp-26 ketamine implant demonstrates successful drug delivery

Initial indications target fibromyalgia and chronic pain loaded and encapsulated drug maintains structural stability as implantable treatment sarasota, fl, feb. 14, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today provided a positive update on sp-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. a pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability.
SILO Ratings Summary
SILO Quant Ranking